20160902140054812_ja.png

web_header_st_en.png

web_icon.png

Announcements

Sessions

Profile management

Search presentations

Bookmark

Download PDF for print

Timetable

Program Type

Live Streaming Available

Late-breaking Abstract

ポスターカテゴリ

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

This archive has moved to the member page of The Molecular Biology Society of Japan. Members can access the abstracts via links at the member page of the sites. Please feel free to contact the journal offices for any inquiries.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Prediction of resistance mutations against Zotizalkib and Gilteritinib in second-line therapy for ALK-positive lung cancer

3. Development and Regeneration - a. Organogenesis / Morphogenesis / Regeneration - b. Stem Cell - c. Cell Differentiation - d. Early Development - e. Reproduction - f. Others 4. Animal and Plant Physiology, and Diseases - a. Symbiotic Microorganism - b. Biological Rhythm - c. Brain / Nervous System / Neurodevelopment / Structure - d. Brain / Nervous System / Behavior - e. Brain / Nervous System / Disorder - f. Immunity - g. Infection / Virus - h. Aging - i. Cancer Cell - j. Cancer Tissue / Cancer Therapeutics - k. Metabolism / Nutrition - l. Genetic Disorder - m. Plant - n. Macrobiology - o. Others

日本分子生物学会年会

The 47th Annual Meeting of the Molecular Biology Society of Japan

The 47th Annual Meeting of the Molecular Biology Society of Japan

[1P-869]Prediction of resistance mutations against Zotizalkib and Gilteritinib in second-line therapy for ALK-positive lung cancer

Password required to view